Enjaymo's targeted mechanism of action inhibits the C1s in the classical complement pathway, preventing the abnormal breakdown of red blood cells. The approval of Enjaymo by the FDA in February ...

utilizing a unique approach targeting the classical complement pathway. In its latest earnings report, Annexon highlighted significant progress in its clinical programs and financial performance ...

Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the ...